Latest news with #AbCelleraBiologicsInc
Business Wire
5 days ago
- Business
- Business Wire
AbCellera to Participate at Upcoming Investor Conferences in September
VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences: Wells Fargo Healthcare Conference, September 3-5, 2025 Morgan Stanley Annual Global Healthcare Conference, September 8-10, 2025 Visit AbCellera's Investor Relations website for additional information. About AbCellera Biologics Inc. AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please visit
Business Wire
07-07-2025
- Business
- Business Wire
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) will announce its second quarter 2025 financial results on Thursday, August 7, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit
Yahoo
09-06-2025
- Business
- Yahoo
AbCellera Biologics Inc. (ABCL): A Bull Case Theory
We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Investment Ides by Antonio's Substack. In this article, we will summarize the bulls' thesis on ABCL. AbCellera Biologics Inc. (ABCL)'s share was trading at $2.14 as of 2nd June. ABCL's trailing P/E was 19.92 according to Yahoo Finance. A biopharmaceutical facility with technicians working on a manufacturing line of treatments and preventions. Abcellera is approaching a potential inflection point as it advances two new molecules—ABCL575 and ABCL635—into clinical trials, signaling its progress from a platform with promise to one capable of solving real-world medical problems. ABCL575 targets the OX-40 pathway, a critical immune regulator, and is being trialed for atopic dermatitis, with broader implications for treating alopecia and other chronic conditions that often stem from underlying viral or bacterial infections. CEO Carl Hansen noted that the same mechanism might have therapeutic value across autoimmune disorders, cancers, and infectious diseases, making OX-40 a cornerstone of Abcellera's ambitions. Meanwhile, ABCL635 targets the NK3R receptor in the brain's infundibular nucleus, effectively regulating endocrine balance and alleviating menopausal hot flashes. Since NK3R is part of the expansive GPCR receptor family, success here could validate Abcellera's ability to target a vast range of physiological functions, from hormone control to mood and sensory regulation. Both candidates exemplify the same core strength of Abcellera's platform: designing molecules with highly specific shapes to achieve precise biological effects. This shape-function relationship underpins the company's long-term vision of building a foundational biotech platform capable of producing tailored therapeutics. Although Abcellera's current financials remain weak, reflecting high risk, clinical success would dramatically increase its operating leverage and establish its relevance across a wide therapeutic spectrum. The platform's success could mirror and complement businesses like Hims, where data on bodily processes meets Abcellera's molecular solutions. While early in its journey, Abcellera's emerging capabilities suggest transformative potential if early trials succeed. Previously, we have covered ABCL in January 2025 wherein we summarized a by Jack Prescott on Twitter. The author highlighted the company's differentiated antibody discovery platform, which used microfluidics and AI to support an asset-light, partnership-driven model with firms like Eli Lilly and Moderna. Despite setbacks post-COVID, AbCellera maintained strong financials with $700M in cash, minimal debt, and over 200 pipeline programs, while its new GMP facility and government support positioned it for future clinical and commercial growth. Unfortunately, his thesis did not play out and the stock is down 26% since our coverage. However, due to the company's recent advances in the clinical trial process of two new molecules, we are optimistic about Antonio's thesis. AbCellera Biologics Inc. (ABCL) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 17 hedge fund portfolios held ABCL at the end of the first quarter which was 20 in the previous quarter. While we acknowledge the potential of ABCL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
21-05-2025
- Business
- Yahoo
AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential
We recently published an article titled . AbCellera Biologics Inc. (NASDAQ:ABCL) was one of the stocks that was covered in that article. Wall Street analysts believe ABCL has a 474% upside potential over the next 12 months. A research team analyzing data on a computer screen, uncovering details about the antibody discovery platform. AbCellera Biologics Inc. (NASDAQ:ABCL) is an AI-powered biotechnology company specializing in antibody discovery. Founded in 2012, the company integrates cutting-edge technology, advanced data science techniques, and interdisciplinary expertise to streamline the development of innovative antibody medicines. These medicines target a range of health issues, including cancer, autoimmune disorders, and metabolic conditions, addressing critical therapeutic needs in the biopharmaceutical landscape. AbCellera's pipeline includes promising candidates such as ABCL635, designed to tackle metabolic and endocrine conditions, and ABCL575, which is focused on treating T-cell-mediated autoimmune conditions like atopic dermatitis. Both programs remain in preclinical stages, with Clinical Trial Applications expected to commence by 2025, a milestone that underscores AbCellera's commitment to advancing its pipeline with precision and speed. AbCellera's success has been bolstered by strategic collaborations with industry giants such as Eli Lilly, Biogen, and AbbVie. These partnerships have enabled the company to leverage partner insights, cutting-edge technologies, and shared expertise to develop highly optimized clinical candidates. Since its inception, AbCellera has initiated an impressive 96 partner programs, with 16 molecules having reached clinical trials, a testament to the effectiveness of its unique platform. The company's focus extends beyond partnerships, as it has heavily invested in its research infrastructure. By the end of 2025, AbCellera aims to complete its clinical manufacturing facilities, a significant step that will position the company to efficiently bring next-generation antibody therapeutics to market while maintaining high standards of innovation and quality. In terms of financial performance, AbCellera Biologics Inc. (NASDAQ:ABCL) demonstrated a solid topline of $4.24 million for the first quarter of 2025, bolstered by milestone payments and antibody discovery collaborations. For the full year 2024, the company reported a topline of $28.8 million, further solidifying its financial robustness. With a substantial cash position of $540 million, AbCellera is well-equipped to sustain its growth trajectory. On 15th May, 2025, analysts downgraded their estimates based on revenue estimates being lower than expectations. Overall, however, analysts remain optimistic about the stock, highlighting an average share price projection of $11.43 over the next twelve months, presenting an upside potential of 474.37%. Overall, AbCellera Biologics Inc. (NASDAQ:ABCL) ranks 7th on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of ABCL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABCL and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
23-04-2025
- Business
- Yahoo
Is AbCellera Biologics Inc. (ABCL) the Best Canadian Penny Stock to Invest in Now?
We recently published a list of In this article, we are going to take a look at where AbCellera Biologics Inc. (NASDAQ:ABCL) stands against other best Canadian penny stocks to invest in now. We define penny stocks as shares trading under $5.00, which usually fall into the small cap category. As illustrated by the performance of thematic ETFs, the small cap factor, which performed well historically, fell out of favor sometime in the mid-2010s and has kept underperforming ever since. The 2023-2024 period brought even stronger underperformance of penny stocks, as the proliferation of the AI trend created disproportionate opportunities across the market, favoring only a handful of large capitalization big tech names. This was an important factor in explaining the difference in cross-country stock market returns as well – for example, the Canadian stock market has largely moved in sync or even occasionally outperformed the US market during the first decade of the century, until a noticeable decoupling took place in the early 2010s. Besides lagging on productivity improvement and different monetary policies, the size factor clearly played a role, as Canada lacks big tech players to capitalize on the rapid technological advancements that took place during the 2010s. READ ALSO: 10 Best Canadian Stocks to Buy According to Billionaires As a result, both the Canadian and small-size factors have found themselves at multi-year lows relative to the US stock market at the end of calendar 2024. While many investors make reactive decisions and avoid stocks with historical underperformance, the smart way to make money is to often take contrarian bets based on forward-looking signals that may suggest a reversal in the previous tendencies. The main questions to answer in this article are the following: will the small cap factor and Canada stocks become favored again and able to outperform their large cap and US counterparts? When discussing the small factor, we get to see that its recent 2023-2024 underperformance was accelerated by rising stock market concentration to record levels. External data suggests that the 2024 US stock market concentration, as measured by the share of the top 10 largest companies in the total market, was at a record 38%, significantly above the historical average of around 24%. This means that most of the stock market returns were driven by a handful of companies favored by AI-related FOMO which overstretched their market valuations. In a scenario where large caps perform well, the small caps fall out of favor automatically, by setup. History shows, however, that concentration tends to revert to the mean – this is already happening in 2025 as the Magnificent 7 ETF, which includes the largest big tech stocks, has significantly underperformed the broad market, decreasing its concentration. Furthermore, the small cap factor tends to perform well when the economy is growing, interest rates are low and capital moves freely to riskier assets – while we aren't there yet, the stock market is a forward-looking animal that tends to anticipate economic developments 6-12 months ahead. We believe small caps and particularly penny stocks may start performing well in anticipation of lower interest rates and better economic conditions in 2026 and beyond, past the current tariff turmoil and other uncertainties induced by rapid policy changes brought by the new US administration. There are reasons to expect an improvement in the performance of Canadian stocks relative to the US market. First, the Trump Tariff Turmoil has much worse potential implications for the US than it does for Canada – the US has put its entire export/import base at risk of retaliation, while Canada only risks tariffs for its US exports (and likely at a lower overall tariff rate). Second, the breaking of economic and ideological ties with the new US administration could lead to an overall mobilization of the Canadian people and political class, and drive several positive developments: (1) substitution of US consumer brands with local Canadian brands; (2) accelerating investments into the mining/energy infrastructure and pipelines to create alternative paths and markets for the main Canadian product, which is commodities. Both (1) and (2) would have positive implications for the entire Canadian stock market and economy. The main takeaway for readers is that combining the small size factor with the Canadian factor could lead to substantial outperformance relative to the US market which witnesses heightened uncertainty and negative returns year-to-date. In such a scenario, Canadian penny stocks appear the ideal securities to pick for a bet on both factors, which would be contrarian to the trends we witnessed in the last 10 years. To compile our list of best Canadian penny stocks we use a stock screener to filter for Canadian companies trading in the US with a stock price below $5.00. Then we compared the list with our proprietary Q4 2024 database of hedge funds' ownership and included in the article the top 13 stocks with the largest number of hedge funds owning the stock, ranked in ascending order. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A research team analyzing data on a computer screen, uncovering details about the antibody discovery platform. As a biotechnology company, AbCellera Biologics Inc. (NASDAQ:ABCL) specializes in the discovery and development of antibody-based therapies for various conditions, including cancer, metabolic and endocrine disorders, and autoimmune diseases. The company employs a proprietary platform that integrates computational tools and other technology to better identify and develop antibodies. ABCL has a promising internal pipeline of preclinical candidates. AbCellera Biologics Inc. (NASDAQ:ABCL) is transitioning from a platform and partnership company to a clinical-stage biotech, with two programs positioned for filings in Q2 2025. The company closed 2024 with over $800 million in available liquidity and completed significant investments in its platform and facilities, including a new headquarters and an upcoming clinical manufacturing facility scheduled to come online in 2025. ABCL has reduced new discovery partnership activities while maintaining a robust portfolio of more than 20 preclinical programs with the potential to become highly differentiated assets. This is the primary factor that earned ABCL the eighth place on our list of the best penny stocks to consider. AbCellera Biologics Inc. (NASDAQ:ABCL) maintains a strong financial position with approximately $650 million in cash and equivalents, plus roughly $190 million in available committed government funding. For 2025, cash usage for operating activities is expected to be similar to 2024, with investments in PP&E at approximately half of 2024 levels and weighted towards the first half of the year. The company believes it has sufficient liquidity to fund well beyond the next 3 years of increasing pipeline investments, with key milestones including clinical starts in 2025, first clinical readouts in 2026, and the election of approximately 2 additional development candidates per year. Overall, ABCL ranks 8th on our list of best Canadian penny stocks to invest in now. While we acknowledge the potential of ABCL to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ABCL but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
